Kapil Uttamrao Raut

Medical Oncologist and Pediatric Oncologist. Clinician,researcher,reader,traveller.

[VJ Oncology @VJOncology]

Venkatraman Radhakrishnan (@venkymd) at #ASCO26 discusses findings from a Phase III non-inferiority trial of olanzapine as prophylaxis for chemotherapy-induced nausea and vomiting in children and adolescents 🏥 Non-inferiority was not demonstrated but complete response rates were broadly comparable 📊🔬

Watch: https://t.co/WiRY46UuMe

#Oncology @ASCO #TrialUpdate #PediatricOncology

[HemOnc Today @HemOncToday]

🤖 An #AI tool predicted about 70% of children with #ALL #Leukemia who would relapse, double that of clinicians.

🗨️ “The model is able to look deeper and find connections which the human brain is not,” @venkymd of Cancer Institute (W.I.A) in India. https://t.co/PTFX7vOuRu

[Venky @venkymd]

Use of Artificial Intelligence to predict relapse in Pediatric Acute Lymphoblastic Leukaemia. ICICLE pre trial cohort. AI performed better than clinicians in predicting relapse. #AI #Cancer #Oncology

[Venky @venkymd]

Limited options for patients with EGFR mutated lung cancer who have progressed on TKI. Our study shows that rechallenging with erlotinib if patient has previously received gefitinib or osimertinib can provide up to 6 months PFS in exon 19 del. https://t.co/K1TX8zsGus @CRSTonline

[Venky @venkymd]

Importance of research in cancer care.
#Oncology #research #cancer

[Keith Siau @drkeithsiau]

“Perfection is impossible.” Many of us are perfectionists and dwell on our failures, but by learning and moving on, only can we fully commit to the next case with “intensity, clarity, and focus.” Words of wisdom from @rogerfederer 🙇🏻‍♂️🤯

[ImmunoACT @ActImmuno]

We are glad to have taken a significant step in providing our CAR-T cell therapies affordably and expandably across India, in collaboration with one of the country's earliest & foremost cancer care centres, @CI_WIA

[Think Global Health @ThinkGlobalHlth]

.@venkymd gave a harrowing account on the struggles that women and girls face in India ranging from female infanticide to inability to receive life-saving care due to their gender.

Read his call to reform institutions and practices to address growing bias https://t.co/rSqiU3kuYd

[Venky @venkymd]

Time to move away from Dexamethasone for prevention of chemotherapy induced nausea and vomiting (CINV).

✅ Phase 3 double blind RCT
✅ DEX free prophylaxis is effective
✅ Lesser side effects like insomnia

https://t.co/dnuHdYoFjC
@JCOGO_ASCO

[ESMO - Eur. Oncology @myESMO]

This @CancerCareMASCC and ESMO Guideline update covers emetic risk classification, prevention & management of chemotherapy- and radiotherapy-induced #nausea & #vomiting, two of the most troublesome adverse events for pts treated w/ antineoplastic therapy. https://t.co/sH973WSatF
#supponc #pallonc @venkymd @PaulaSayegh @oncoblogger @bosnjaksupport @Anchyly @ESMO_Open #ESMOGuidelines

[Mangalam Maloo @blitzkreigm]

This is the most thrilling 2 mins of badminton I’ve seen in a while

Korea vs Malaysia!

The tension towards the end is insane :)

https://t.co/Ywq1FnqQnp

[Venky @venkymd]

Reduction in chemo dose intensity by 25% and adding Rituximab improves survival in pediatric high grade B Non Hodgkins Lymphoma in resource limited settings.
https://t.co/qINsSIaIO2
Outcomes comparable to high income countries. A 25% improvement in survival compared to past.

[Sujith @sujithonco]

Salutes to you Sir for a revolution in Oncology care you have brought in.

Inspiration for all of us is your Life with immense passion and Commitment towards Oncology care for every human being irrespective of the place they live and money they have

@IndianYoungOnco

[Shalini Vinod @shalinivinod13]

Dr Joyita Banerjee speaks on the 5 M's to optimise #Gerionc care for older patients with cancer @SIOGorg @VanitaNoronha

[Venky @venkymd]

Poster presentation at a big meeting like #ASCO23 can be humbling. You go with the idea that your research is path breaking and exciting, only to realize that most don't share your enthusiasm. It's just you and your poster and no one turns up. Sitting all alone you reflect

[Dr Amol Akhade @SuyogCancer]

Upfront Osimertinib vs geftinib followed by Osimertinib . APPLE trial . SAME OS. Better brain pfs for upfront osi.CtDNA to pick up progression earlier than radiological imaging. @myESMO #ELCC23 @JackWestMD @PatelOncology @StephenVLiu @n8pennell @DrSteveMartin @ADesaiMD

[Jarushka Naidoo @DrJNaidoo]

Pleased to publish the EGFRmt subgrp analysis of PACIFIC: Durvalumab post ChemoRT in Stage III NSCLC @JTOonline

- 35pts (durva=24 pbo=11)
- mPFS 11.2 v 10.9m
- mOS 46.8 v 43m HR 1.02

No clear benefit but also no clear harm, await LAURA trial results https://t.co/Gi04sV9AUO

[Kapil Uttamrao Raut @RAUTKAPIL]

@SiopAsia2023 @venkymd Congratulations sir @venkymd

[Venky @venkymd]

@CI_WIA has been selected by @WHOSEARO as one of the centers for the South-East Asia Regional Childhood Cancer Network (SEAR CCN). Thank you WHO for the opportunity given to Cancer Institute (W.I.A) for being a voice and agent of change for pediatric cancers.
#PediatricOncology